mUC
Showing 1 - 25 of 329
Advanced Breast Cancer, Breast Tumor Malignant Female Trial in Guangzhou (AJMUC1- PD-1 gene knockout anti-MUC1 CAR-T cells)
Completed
- Advanced Breast Cancer
- Breast Neoplasm Malignant Female
- AJMUC1- PD-1 gene knockout anti-MUC1 CAR-T cells
-
Guangzhou, Guangdong, ChinaSun Yat-sen Memorial Hospital of Sun Yat-sen University
Apr 11, 2023
Urothelial Carcinoma Trial in Shanghai (AZD4547, Tislelizumab)
Recruiting
- Urothelial Carcinoma
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Mar 8, 2023
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Phoenix (Autologous MUC1-activated T-cells,
Recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Autologous MUC1-activated T-cells
- Cyclophosphamide
-
Phoenix, ArizonaMayo Clinic Hospital in Arizona
Jan 4, 2023
Solid Tumor, Adult Trial in Beijing (Vaccine)
Not yet recruiting
- Solid Tumor, Adult
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
Aug 3, 2023
HER2 and LA/mUC: A Multi-country Chart Review Cohort Study
Not yet recruiting
- Urothelial Carcinoma
- (no location specified)
Jun 5, 2023
Solid Tumors Trial in New York (procedure, drug, device, genetic)
Active, not recruiting
- Solid Tumors
- Production of Genetically-modified T cells
- +4 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Sep 1, 2022
Munich ME/CFS Cohort Study
Recruiting
- Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) (ICD-10 G93.3)
-
Munich, Bavaria, GermanyMRI Chronic Fatigue Center for Young People (MCFC), Children's h
Aug 16, 2023
Breast Cancer, Ovarian Cancer, Non Small Cell Lung Cancer Trial in San Francisco, Denver, San Antonio (P-MUC1C-ALLO1 CAR-T
Recruiting
- Breast Cancer
- +8 more
- P-MUC1C-ALLO1 CAR-T cells
- Rimiducid
-
San Francisco, California
- +4 more
Oct 26, 2022
Metastatic Breast Cancer Trial in Duarte (huMNC2-CAR44 CAR T cells, huMNC2-CAR44 CAR T cells @ RP2D)
Recruiting
- Metastatic Breast Cancer
- huMNC2-CAR44 CAR T cells
- huMNC2-CAR44 CAR T cells @ RP2D
-
Duarte, CaliforniaCity of Hope Medical Center
Dec 22, 2021
Lung Carcinoma Trial in Rochester, Pittsburgh (Laboratory Biomarker Analysis, MUC1 Peptide-Poly-ICLC Vaccine)
Active, not recruiting
- Lung Carcinoma
- Laboratory Biomarker Analysis
- MUC1 Peptide-Poly-ICLC Vaccine
-
Rochester, Minnesota
- +1 more
Feb 24, 2022
Locally Advanced Pancreatic Adenocarcinoma, Pancreatic Acinar Cell Carcinoma, Pancreatic Ductal Adenocarcinoma Trial in New
Active, not recruiting
- Locally Advanced Pancreatic Adenocarcinoma
- +4 more
- Falimarev
- +3 more
-
New Brunswick, New JerseyRutgers Cancer Institute of New Jersey
Jan 4, 2022
Headache, Migraine, Multiple Sclerosis Trial in New York (RELAXaHEAD app, Monitored Usual Care (MUC))
Completed
- Headache
- +2 more
- RELAXaHEAD app
- Monitored Usual Care (MUC)
-
New York, New YorkNew York University School of Medicine
Jul 6, 2022
Migraine Trial in New York (PMR (Progressive muscle relaxation therapy), Monitored Usual Care (MUC))
Completed
- Migraine
- PMR (Progressive muscle relaxation therapy)
- Monitored Usual Care (MUC)
-
New York, New YorkNYU Langone
Sep 20, 2022
Metastatic Colorectal Cancer Trial run by the National Cancer Institute (NCI) (Retifanlimab, Therapeutic CEA, Brachyury and MUC1
Not yet recruiting
- Metastatic Colorectal Cancer
- Retifanlimab
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Dec 4, 2023
Metastatic Urothelial Carcinoma, Urothelial Tumors Trial (Coformulated favezelimab/pembrolizumab, Coformulated
Not yet recruiting
- Metastatic Urothelial Carcinoma
- Urothelial Neoplasms
- Coformulated favezelimab/pembrolizumab
- +3 more
- (no location specified)
Apr 26, 2023
Migraine, Headache, Multiple Sclerosis Trial in New York (Smartphone-Based Progressive Muscle Relaxation Therapy (PMR),
Recruiting
- Migraine
- +3 more
- Smartphone-Based Progressive Muscle Relaxation Therapy (PMR)
- Monitored Usual Care (MUC)
-
New York, New YorkNYU Langone Health
Jul 18, 2022
Acute Myeloid Leukemia, in Relapse, Recurrent Adult Acute Myeloid Leukemia Trial in Boston (GO-203-2c, GO-203-2c + Decitabine)
Active, not recruiting
- Acute Myeloid Leukemia, in Relapse
- Recurrent Adult Acute Myeloid Leukemia
- GO-203-2c
- GO-203-2c + Decitabine
-
Boston, Massachusetts
- +1 more
Jan 25, 2022
Urine Omics Predicting IO Therapy Responses in mUC Patients
Recruiting
- Metastatic Urothelial Carcinoma
- No intervention required
-
Taipei, TaiwanNational Taiwan University Hospital
Dec 19, 2021
Lung Cancer, Cancer, Immunotherapy Trial in Guangzhou (CAR-T cells targeting PSCA, MUC1, TGFß, HER2, Mesothelin, Lewis-Y, GPC3,
Recruiting
- Lung Cancer
- +3 more
- CAR-T cells targeting PSCA, MUC1, TGFβ, HER2, Mesothelin, Lewis-Y, GPC3, AXL, EGFR, Claudin18.2, or B7-H3
-
Guangzhou, Guangdong, China
- +1 more
Nov 26, 2021
Head and Neck Squamous Cell Carcinoma, Head Neck Cancer Trial in Miami (drug, biological, other)
Completed
- Head and Neck Squamous Cell Carcinoma
- Head and Neck Cancer
- Tadalafil
- +6 more
-
Miami, FloridaUniversity of Miami
Jun 10, 2021
Enterostomy Trial in Austria, Germany, Netherlands (mucous fistula refeeding)
Recruiting
- Enterostomy
- mucous fistula refeeding
-
Graz, Austria
- +14 more
Mar 16, 2022
Recurrent Non-Small Cell Lung Carcinoma, Stage I NSCLC, Stage II NSCLC Trial in United States (TG4010, Nivolumab)
Completed
- Recurrent Non-Small Cell Lung Carcinoma
- +5 more
- TG4010
- Nivolumab
-
Duarte, California
- +3 more
Oct 11, 2021